Nodehi, Reza Safaei
Kalantari, Behjat
Raafat, Jahangir
Ansarinejad, Nafiseh
Moazed, Vahid
Mortazavizadeh, Seyed Mohammad Reza
Hosseinzadeh, Mehran
Ghaderi, Bayazid
Jenabian, Arash
Qadyani, Mojtaba
Haghighat, Shirin
Allahyari, Abolghasem
Mirzania, Mehrzad
Seghatoleslami, Mohammad
Payandeh, Mehrdad
Alikhasi, Afsaneh
Kafi, Hamidreza
Shahi, Farhad
Funding for this research was provided by:
AryoGen Pharmed Co.
Article History
Received: 20 December 2021
Accepted: 19 July 2022
First Online: 28 July 2022
Declarations
:
: The study was performed in accordance with Good Clinical Practice (GCP) guidelines and the Declaration of Helsinki.Each participant signed a written informed-consent form before the initiation of the trial.Research Ethics Committee of Tehran University of Medical Sciences: (IR.TUMS.REC.1395.2730).Research Ethics Committee of Isfahan University of Medical Sciences: (IR.MUI.REC.1395.4.041).ExternalRef removed registration code: (NCT03425656) - First registered on 07/02/2018.Iranian Registry of Clinical Trials (IRCT) registration code: IRCT201606226135N7 - First registered on 25/06/2016.
: Not applicable.
: Hamidreza Kafi is the head of the medical department of Orchid Pharmed Company, which is in collaboration with AryoGen Company with respect to conducting clinical trials. No other potential conflicts of interest relevant to this article were reported.